- Investing.com
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Resilient Performance | Sotera Health surpasses expectations with strong Q3 results, reaffirming full-year guidance of 4-6% growth in revenue and EBITDA for FY 2024 |
Regulatory Compliance | Explore how Sotera's proactive NESHAP compliance may reduce future EO litigation risks and enhance its competitive edge in the sterilization market |
Market Dynamics | Delve into the positive momentum in the MedTech sector and how Sotera Health is positioned to benefit from increasing healthcare-related manufacturing activities |
Analyst Perspectives | Average price target of $17.20, with analysts maintaining positive outlooks despite ongoing litigation concerns and potential market challenges |
Metrics to compare | SHC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSHCPeersSector | |
---|---|---|---|---|
P/E Ratio | 52.8x | −11.6x | −0.7x | |
PEG Ratio | 0.43 | −0.58 | 0.00 | |
Price/Book | 7.9x | 1.9x | 2.6x | |
Price / LTM Sales | 3.3x | 2.8x | 3.2x | |
Upside (Analyst Target) | 23.8% | 21.0% | 46.6% | |
Fair Value Upside | Unlock | 1.9% | 7.4% | Unlock |